Highlights
NASDAQ: INCY       Incyte Corp
Last Price Today's Change   Day's Range   Trading Volume
87.49   +0.79 (0.91%)  86.35 - 88.00  815,251

Overview

 
Avg Volume (4 weeks):997,400
4 Weeks Range:76.27 - 88.00
4 Weeks Price Volatility (%):
95.65%
52 Weeks Range:57.00 - 89.30
52 Weeks Price Volatility (%):
94.40%
Average Price Target: 120.00
Price Target Upside/Downside: +32.51

Headlines



No recent Headlines for this stock.


Business Background

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

  Be the first to like this.
 


 

2604  3075  374  2926 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 CHK 0.644-0.057 
 AMD 39.88+1.32 
 ACB 2.28-0.45 
 I 8.03-5.38 
 AABA 19.630.00 
 GE 11.44-0.08 
 UBER 26.75-0.04 
 AMRN 22.60-1.42 
 F 8.950.00 
 SNAP 14.69+0.75 
Partners & Brokers